The present invention relates to ophthalmic and non-ophthalmic systems with blue light filtering and Yellowness Index ranges. UV and IR filtering are also included. Industrial applications are also outlined in the invention.

The present invention relates to a composition comprising: (a) at least one cinnamic acid derivative according to a specific chemical formula; (b) at least one lipophilic antioxidant; (c) at least one oil; and (d) water, wherein the pH of the composition is 4.5 or less. The composition according to the present invention is stable under a variety of temperature conditions.

The present invention involves the formation of host-guest complexes between C-methylresorcin[4]arene and Oxybenzone (OXB). NMR spectroscopy confirmed the formation of a weak host-guest complex and molecular dynamics docking simulations indicated that this complex likely had a 1:1 stoichiometry. Furthermore, skin permeation testing revealed that complexation by C-methylresorcin[4]arene significantly reduced the amount of OXB that permeated skin. These results show the potential of supramolecular complexation for improving the stability and decreasing the skin permeability of OXB, thus limiting harmful side effects.

The present invention involves the formation of host-guest complexes between C-methylresorcin[4]arene and Oxybenzone (OXB). NMR spectroscopy confirmed the formation of a weak host-guest complex and molecular dynamics docking simulations indicated that this complex likely had a 1:1 stoichiometry. Furthermore, skin permeation testing revealed that complexation by C-methylresorcin[4]arene significantly reduced the amount of OXB that permeated skin. These results show the potential of supramolecular complexation for improving the stability and decreasing the skin permeability of OXB, thus limiting harmful side effects.

Surface-modified zinc oxide particles which have a silane coupling agent having an alkoxy group on surfaces thereof, in which d50 when measured with a laser diffraction/scattering type particle size distribution-measuring instrument by the following measurement method is 4 μm or less. (Measurement method) 10 g of the surface-modified zinc oxide particles, 88 g of cyclopentasiloxane, and 2 g of polyglyceryl-3 polydimethylsiloxyethyl dimethicone are mixed to obtain a liquid mixture, a dispersion treatment is performed on the obtained liquid mixture at 9,500 rpm for 5 minutes using a homogenizer to obtain a liquid dispersion, the liquid dispersion is diluted with cyclopentasiloxane so that a content of the surface-modified zinc oxide particles in the obtained liquid dispersion is 0.01% by mass to produce a measurement solution, and d50 is measured with the laser diffraction/scattering type particle size distribution-measuring instrument using the obtained measurement solution.

Surface-modified zinc oxide particles which have a silane coupling agent having an alkoxy group on surfaces thereof, in which d50 when measured with a laser diffraction/scattering type particle size distribution-measuring instrument by the following measurement method is 4 μm or less. (Measurement method) 10 g of the surface-modified zinc oxide particles, 88 g of cyclopentasiloxane, and 2 g of polyglyceryl-3 polydimethylsiloxyethyl dimethicone are mixed to obtain a liquid mixture, a dispersion treatment is performed on the obtained liquid mixture at 9,500 rpm for 5 minutes using a homogenizer to obtain a liquid dispersion, the liquid dispersion is diluted with cyclopentasiloxane so that a content of the surface-modified zinc oxide particles in the obtained liquid dispersion is 0.01% by mass to produce a measurement solution, and d50 is measured with the laser diffraction/scattering type particle size distribution-measuring instrument using the obtained measurement solution.

The invention relates to a dispersion containing at least one rhamnolipid derivative and also to the use of the rhamnolipid derivatives as emulsifier or dispersing aid.

The invention relates to a dispersion containing at least one rhamnolipid derivative and also to the use of the rhamnolipid derivatives as emulsifier or dispersing aid.

The present invention provides wound healing compounds, compositions thereof, and methods of treatment using the same.

The present invention provides wound healing compounds, compositions thereof, and methods of treatment using the same.